VEGF R2/KDR hFc Chimera, Human
VEGF R2/KDR HFc Chimera, Human

The purity of VEGF R2/KDR hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

VEGF R2/KDR HFc Chimera, Human

VEGF R2/KDR hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

VEGF R2/KDR HFc Chimera, Human

Immobilized Human VEGF165, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve forVEGF R2/KDR hFc Chimera, Human with the EC50 of 7.8 ng/ml determined by ELISA.

VEGF R2/KDR HFc Chimera, Human

Immobilized VEGF R2/KDR hFc Chimera, Human, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-VEGF R2 Antibody, hFc Tag with the EC50 of 9.7ng/ml determined by ELISA.

VEGF R2/KDR hFc Chimera, Human

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis.
Z03965
¥55,963.00

Ask us a question
Product Introduction
Species Human
Protein Construction
VEGF R2/KDR (Ala20-Glu764)
Accession # P35968-1		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 109.21 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 150-180 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4).
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • VEGF R2/KDR HFc Chimera, Human
    • VEGF R2/KDR HFc Chimera, Human

    The purity of VEGF R2/KDR hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • VEGF R2/KDR HFc Chimera, Human
    • VEGF R2/KDR HFc Chimera, Human

    VEGF R2/KDR hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • VEGF R2/KDR HFc Chimera, Human
    • VEGF R2/KDR HFc Chimera, Human

    Immobilized Human VEGF165, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve forVEGF R2/KDR hFc Chimera, Human with the EC50 of 7.8 ng/ml determined by ELISA.

  • VEGF R2/KDR HFc Chimera, Human
    • VEGF R2/KDR HFc Chimera, Human

    Immobilized VEGF R2/KDR hFc Chimera, Human, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-VEGF R2 Antibody, hFc Tag with the EC50 of 9.7ng/ml determined by ELISA.


Background
Target Background Vascular endothelial growth factor receptor 2 (VEGFR2) is one kind of tyrosine kinase receptors. VEGFR2 acts as a cell-surface receptor for VEGFA, VEGFB and PGF. It plays an important role in the development of embryonic vasculature, cell survival and cancer cell invasion. VEGFR2 is a key regulator of angiogenesis.
Synonyms CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.